Lifecycle Pharma, Inc. Sustainability Profile
Lifecycle Pharma, Inc., commonly referred to as Lifecycle Pharma, is a prominent biopharmaceutical company headquartered in the United States. Founded in the early 2000s, the company has established itself within the pharmaceutical industry, focusing on the development of innovative therapies for chronic diseases, particularly in the areas of respiratory and metabolic disorders. Lifecycle Pharma is renowned for its unique drug delivery systems and formulations, which enhance the efficacy and patient compliance of existing treatments. The company has achieved significant milestones, including successful clinical trials and partnerships that bolster its market position. With a commitment to advancing healthcare solutions, Lifecycle Pharma continues to make strides in improving patient outcomes through its specialised products and services.
DitchCarbon Score
How does Lifecycle Pharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lifecycle Pharma, Inc.'s score of 52 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Lifecycle Pharma, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Asahi Kasei Corporation, and any emissions data or climate commitments may be inherited from this parent organisation. Asahi Kasei Corporation, at the third cascade level, has established various climate initiatives, although specific reduction targets or achievements for Lifecycle Pharma, Inc. have not been detailed. The absence of documented reduction targets or climate pledges indicates that Lifecycle Pharma may still be in the process of developing its own sustainability strategies. In the context of the industry, Lifecycle Pharma, Inc. is expected to align with broader corporate climate commitments, potentially influenced by Asahi Kasei's sustainability goals. However, without specific emissions data or targets, it is challenging to assess the company's current carbon footprint or its commitment to reducing greenhouse gas emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000,000 | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 2 | - | 0,000,000,000 | - | - | - | - | - | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000,000 | 0,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 |
How Carbon Intensive is Lifecycle Pharma, Inc.'s Industry?
How Carbon Intensive is Lifecycle Pharma, Inc.'s Location?
Lifecycle Pharma, Inc.'s Scope 3 Categories Breakdown
Lifecycle Pharma, Inc.'s Scope 3 emissions, which decreased by 0% last year and increased by approximately 113% since 2015, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 79% of total emissions under the GHG Protocol, with "End-of-Life Treatment of Sold Products" being the largest emissions source at 41% of Scope 3 emissions.
Top Scope 3 Categories
Lifecycle Pharma, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Lifecycle Pharma, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
